AI Science Tracker
EN

Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.

Department of Pharmacy, Honghui Hospital, Xi' an Jiaotong University, Xi' an, 710054, China.; Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.; State Key Laboratory of Natural Medicines,Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery,China Pharmaceutical University, Nanjing, 210009, China. · 28 Aug 2023 · chemistry

Discovery

Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.

Source check: Source checked. Not independent scientific confirmation.

Finding: ML and structure-based pharmacophore screening identify JAK1 inhibitor candidates; four purchasable compounds were bio-evaluated and Z-10 showed kinase inhibition (IC50 194.9 nM). Experimental biochemical validation supports a specific inhibitor candidate; no therapeutic efficacy is claimed. AI role: Machine-learning classifiers with pharmacophore screening. The article appeared in Journal Of Translational Medicine.

Technology: Machine-learning classifiers with pharmacophore screening

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Machine-learning classifiers with pharmacophore screening
Test and result
ML and structure-based pharmacophore screening identify JAK1 inhibitor candidates; four purchasable compounds were bio-evaluated and Z-10 showed kinase inhibition (IC50 194.9 nM). Experimental biochemical validation supports a specific inhibitor candidate; no therapeutic efficacy is claimed.
Limitation / still unknown
The result is limited to the described dataset, cohort, experimental system, or validation design; generalization beyond that scope and downstream real-world benefit are not established. Author affiliation was not stated in the reviewed abstract or metadata.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1186/s12967-023-04443-6 · https://pubmed.ncbi.nlm.nih.gov/37641144/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse chemistry discoveries.